EyePoint Pharmaceuticals, Inc.
11.73-0.52 (-4.24%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · EYPT · USD
Key Stats
Market Cap
947.24MP/E (TTM)
-Basic EPS (TTM)
-2.69Dividend Yield
0%Recent Filings
8-K
Phase 3 DME program launches
EyePoint Pharmaceuticals announced its Phase 3 program for DURAVYU in diabetic macular edema, with first patient dosing set for Q1 2026 following FDA alignment on a non-inferiority pathway versus aflibercept. New preclinical data reveals vorolanib's dual inhibition of VEGF and IL-6-mediated inflammation, bolstering Phase 2 VERONA results that showed rapid vision gains and reduced treatment burden. This multi-mechanism approach targets DME's vascular and inflammatory drivers. Cash stands at $200M, funding into 2027.
10-Q
Q2 FY2025 results
EyePoint Pharmaceuticals posted Q2 revenue of $5.3 million, down 44% year-over-year from $9.5 million, driven by lower license recognition from the ANI YUTIQ deal and no product sales, though YTD revenue jumped 41% to $29.8 million thanks to $12.7 million in royalty income from the terminated SWK agreement. R&D expenses surged 86% to $55.5 million, fueled by Phase 3 trials for DURAVYU in wet AMD, pushing operating loss to $62.2 million (up 80% y/y) and net loss to $59.4 million, or $0.85 per diluted share on 69.9 million shares. Cash burn intensified with $115.7 million used in operations, leaving $255.7 million in cash and marketable securities to fund into 2027. Enrollment wrapped in both LUGANO and LUCIA trials. Cash stretches far. Yet regulatory hurdles in retinal trials loom large.
8-K
Phase 3 enrollment complete
EyePoint Pharmaceuticals completed enrollment in its Phase 3 wet AMD trials, LUGANO and LUCIA, randomizing over 800 patients in seven months each, signaling strong interest in DURAVYU's sustained-release therapy. Q2 revenue fell to $5.3 million from $9.5 million year-over-year, while operating expenses surged to $67.6 million on trial costs, yielding a $59.4 million net loss. Cash stands at $256 million, funding operations into 2027 past 2026 topline data. Enrollment flew fast.
8-K
Phase 3 enrollment complete
EyePoint Pharmaceuticals completed enrollment in its pivotal Phase 3 LUCIA trial for DURAVYU in wet AMD on July 29, 2025, following LUGANO's finish in May, with over 800 patients randomized across both in under a year. This rapid pace signals strong retinal community support for the sustained-release TKI, backed by consistent safety from prior trials and DSMC approval to proceed. Topline LUGANO data arrives mid-2026. Enrollment flew by fast.
8-K
Stockholders approve plan amendment
EyePoint Pharmaceuticals stockholders approved an amendment to the 2023 Long-Term Incentive Plan at the June 18, 2025 annual meeting, boosting authorized shares by 2,900,000 to support equity awards. The measure passed with 41.3 million for and 13.0 million against, amid strong director elections and executive pay approval. This bolsters talent retention. Yet dilution looms for shareholders.
KALA
KALA BIO, Inc.
0.80-0.03
KOD
Kodiak Sciences Inc
18.93-0.32
KPRX
Kiora Pharmaceuticals, Inc.
2.53+0.08
OCS
Oculis Holding AG
21.55+0.55
OCUL
Ocular Therapeutix, Inc.
11.48-0.05
OKYO
OKYO Pharma Limited
2.72+0.17
OPT
Opthea Limited
3.41+0.00
SRPT
Sarepta Therapeutics, Inc.
23.45-0.77
TARS
Tarsus Pharmaceuticals, Inc.
67.52-0.04
UNBX
Unity Biotechnology, Inc.
0.06+0.00